Karyopharm Therapeutics (KPTI) Net Margin (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Net Margin came in at 200.48% in Q2 2026, down 10226.0% on a YoY basis from N/an in Q2 2025, and down 12.01% quarter-over-quarter from 178.98% in Q4 2025.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Net Margin (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has reported Net Margin for 15 consecutive years, with 200.48% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 10226.0% year-over-year to 200.48%; the trailing twelve-month figure through Jun 2026 stood at 132.72% (down 4265.0% YoY), and the FY2025 full-year result was 106.0%, down 5333.0% from the prior year.
- Net Margin slipped to 200.48% in Q2 2026 per KPTI's latest filing, from 178.98% in the prior quarter.
- Across five years, Net Margin topped out at 55.61% in Q2 2024 and bottomed at 200.48% in Q2 2026.
- Historically, Net Margin has averaged 99.76% across 5 years, with a median of 98.22% in 2025.
- The sharpest annual moves came in 2022 and 2025: Net Margin soared 15999 bps in 2022, then tumbled 15382 bps in 2025.
- Over 5 years, Net Margin stood at 117.42% in 2022, then slipped by 6 bps to 124.7% in 2023, then climbed by 19 bps to 101.04% in 2024, then sank by 77 bps to 178.98% in 2025, then slipped by 12 bps to 200.48% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 200.48%, 178.98%, and 75.21% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 446.22 Bn | 439.65 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 357.04 Bn | 349.90 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 268.38 Bn | 260.69 Bn | 11.24 Bn | 22.65% |
| 5 | Pfizer | 156.32 Bn | 144.62 Bn | 10.94 Bn | -1.58% |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | 2.96% |
| 7 | Revolution Medicines | 43.18 Bn | 43.18 Bn | - | - |
| 8 | Incyte | 24.85 Bn | 20.31 Bn | 1.57 Bn | 34.98% |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn | 42.51% |
| 10 | Karyopharm Therapeutics | 47.02 Mn | -18.08 Mn | 32.35 Mn | -200.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -200.48% |
| Dec 31, 2025 | -178.98% |
| Sep 30, 2025 | -75.21% |
| Jun 30, 2025 | -98.22% |
| Mar 31, 2025 | -78.17% |
| Dec 31, 2024 | -101.04% |
| Sep 30, 2024 | -82.70% |
| Jun 30, 2024 | 55.61% |
| Mar 31, 2024 | -112.79% |
| Dec 31, 2023 | -124.70% |
| Sep 30, 2023 | -95.83% |
| Jun 30, 2023 | -86.83% |
| Mar 31, 2023 | -88.19% |
| Dec 31, 2022 | -117.42% |
| Sep 30, 2022 | -100.50% |
| Jun 30, 2022 | -123.65% |
| Mar 31, 2022 | -86.84% |
| Dec 31, 2021 | 30.64% |
| Sep 30, 2021 | -137.47% |
| Jun 30, 2021 | -237.08% |